Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 9 and August 12, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed transactions involving United Therapeutics Corp [UTHR] common stock.
- These transactions included the exercise of stock options and subsequent sales of common stock on August 9 and August 12, 2024.
- The exercises were conducted at a price of $129.49 per share.
- The sales were executed at varying prices, with weighted average prices ranging from $328.7361 to $336.86.
- These transactions were carried out under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- Following these transactions, Rothblatt directly owns a reduced number of common stock shares, but maintains indirect ownership through various family trusts.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock transactions under a pre-existing plan. There is no indication of positive or negative implications for the company's performance.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of a tranche of 723,869 stock options that expire December 31, 2024.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common among publicly traded companies. The use of a 10b5-1 plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
- Companies like Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings related to stock option exercises and sales by their executives.
- The specific volume and pricing of these transactions are unique to United Therapeutics and its executive compensation structure.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership structure.
- The impact on employees, customers, suppliers, and creditors is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Original date of stock options exercisable |
| 08/04/2023 | Date of establishment of the 10b5-1 trading plan |
| 08/09/2024 | Date of stock option exercise and sale transactions |
| 08/12/2024 | Date of stock option exercise and sale transactions |
| 08/13/2024 | Date of report |
| 08/31/2024 | Potential expiration date of the 10b5-1 trading plan |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.